News | April 22, 2022
WHO recommends Paxlovid for Covid-19 therapy
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Within a fortnight, over 200 contestants sent their entries for the competition, and 30 names were shortlisted after screening entries under different categories
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
The business is a recognized leader in managing Covid-19 and mRNA research programs
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Flutura to deploy Cerebra Digital Twin & Pharmacologist Workbench, a self-service AI platform to accelerate impact on Pharmaceutical outcomes
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Subscribe To Our Newsletter & Stay Updated
